RxDoctor Payments Data

Brian Lea, MD

Cardiovascular Disease · Paducah, KYNPI 1962665364

Payments from drug & device makers

$3,810in general payments, 2019–2025

Across 169 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$795
  • Abbott$558
  • Medtronic$337
  • Merck$303
  • Inari Medical, Inc.$200
  • E.r. Squibb & Sons, L.L.C.$199
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,796100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,810 in reported general payments places this provider in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$266,414
Medicare patients
1,941
Services billed
4,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban672$610,495
JardianceEmpagliflozin346$274,238
EntrestoSacubitril/Valsartan257$227,301
XareltoRivaroxaban133$141,002
FarxigaDapagliflozin Propanediol64$46,416
Repatha SureclickEvolocumab55$40,829
Repatha SyringeEvolocumab46$35,137
BrilintaTicagrelor41$23,971
Praluent PenAlirocumab38$18,821
Metoprolol Succinate620$7,422
Ranolazine ErRanolazine47$5,968
Diltiazem 24hr Er (Cd)Diltiazem Hcl147$3,981
Flecainide Acetate78$3,256
Atorvastatin Calcium527$3,131
Amiodarone Hcl48$2,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$610,495672 claims
Boehringer IngelheimJardiance$114$274,238346 claims
NovartisEntresto$795$227,301257 claims
Johnson & JohnsonXarelto$39$141,002133 claims
AstraZenecaFarxiga, Brilinta$189$70,387105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →